In the context of IBD, a number of therapies have involved the development of antibodies or small molecules designed to interfere with CCR9-CCL25 or α4β7-MadCAM1 interactions to prevent the recruitment of T-cells into the inflamed gut mucosa [53,54]. The gene discussed is CCL25; the disease is inflammatory bowel disease.